diallyl trisulfide has been researched along with Liver Steatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Agamy, DS; Shaaban, AA | 1 |
| Chen, LY; Chen, Q; Cheng, YF; Jin, HH; Kong, DS; Shao, JJ; Wu, L; Zhang, F; Zheng, SZ | 1 |
2 other study(ies) available for diallyl trisulfide and Liver Steatosis
| Article | Year |
|---|---|
Cytoprotective effects of diallyl trisulfide against valproate-induced hepatotoxicity: new anticonvulsant strategy.
Topics: Allyl Compounds; Animals; Anti-Inflammatory Agents; Anticonvulsants; Antioxidants; Apoptosis; Chemical and Drug Induced Liver Injury; Cytoprotection; Disease Models, Animal; Fatty Liver; In Situ Nick-End Labeling; Inflammation; Inflammation Mediators; Male; Mice; NF-kappa B; Oxidative Stress; Rats; Rats, Sprague-Dawley; Seizures; Sulfides; Valproic Acid | 2017 |
Diallyl trisulfide attenuates ethanol-induced hepatic steatosis by inhibiting oxidative stress and apoptosis.
Topics: Allyl Compounds; Animals; Apoptosis; Cell Line; Ethanol; Fatty Liver; Hepatocytes; Humans; Liver; Male; Oxidative Stress; Protective Agents; Rats, Sprague-Dawley; Sulfides | 2016 |